The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with
The post Artax Biopharma to develop oral small molecule immunomodulating agent appeared first on Pharmaceutical Business review.